| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTPN9 |
| Uniprot No | P43378 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-593aa |
| 氨基酸序列 | MEPATAPRPD MAPELTPEEE QATKQFLEEI NKWTVQYNVS PLSWNVAVKF LMARKFDVLR AIELFHSYRE TRRKEGIVKL KPHEEPLRSE ILSGKFTILN VRDPTGASIA LFTARLHHPH KSVQHVVLQA LFYLLDRAVD SFETQRNGLV FIYDMCGSNY ANFELDLGKK VLNLLKGAFP ARLKKVLIVG APIWFRVPYS IISLLLKDKV RERIQILKTS EVTQHLPREC LPENLGGYVK IDLATWNFQF LPQVNGHPDP FDEIILFSLP PALDWDSVHV PGPHAMTIQE LVDYVNARQK QGIYEEYEDI RRENPVGTFH CSMSPGNLEK NRYGDVPCLD QTRVKLTKRS GHTQTDYINA SFMDGYKQKN AYIGTQGPLE NTYRDFWLMV WEQKVLVIVM TTRFEEGGRR KCGQYWPLEK DSRIRFGFLT VTNLGVENMN HYKKTTLEIH NTEERQKRQV THFQFLSWPD YGVPSSAASL IDFLRVVRNQ QSLAVSNMGA RSKGQCPEPP IVVHCSAGIG RTGTFCSLDI CLAQLEELGT LNVFQTVSRM RTQRAFSIQT PEQYYFCYKA ILEFAEKEGM VSSGQNLLAV ESQ |
| 预测分子量 | 60 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTPN9重组蛋白的3篇假设参考文献及摘要概括，供参考：
1. **《Recombinant Human PTPN9 Phosphatase: Purification and Substrate Specificity Analysis》**
- 作者：Zhang Y. et al.
- 摘要：本研究成功在大肠杆菌中表达并纯化重组人PTPN9蛋白，通过体外磷酸酶活性实验，证实其对酪氨酸磷酸化肽段具有特异性去磷酸化作用，并揭示了关键催化结构域的功能突变对其活性的影响。
2. **《PTPN9 Recombinant Protein Suppresses HER2 Signaling in Breast Cancer Cells》**
- 作者：Li X. et al.
- 摘要：利用重组PTPN9蛋白进行体外结合实验，发现其直接与HER2受体相互作用，抑制其酪氨酸磷酸化，进而阻断下游MAPK/ERK通路，提示PTPN9可能在乳腺癌靶向治疗中具有潜在应用。
3. **《Role of PTPN9 in Insulin Resistance: Insights from Recombinant Protein-Based Assays》**
- 作者：Wang H. et al.
- 摘要：通过重组PTPN9蛋白与胰岛素受体β亚基的体外互作实验，证明PTPN9通过去磷酸化作用负调控胰岛素信号通路，为阐明其在2型糖尿病胰岛素抵抗中的作用机制提供了证据。
*注：以上文献为假设示例，实际研究中请通过学术数据库检索具体文献。*
**Background of PTPN9 Recombinant Protein**
PTPN9 (Protein Tyrosine Phosphatase Non-Receptor Type 9), also known as MEG2. is a member of the protein tyrosine phosphatase (PTP) family, which plays critical roles in regulating cellular signaling by dephosphorylating tyrosine residues on target proteins. This enzyme is encoded by the *PTPN9* gene in humans and is involved in modulating key processes such as cell growth, differentiation, metabolism, and immune responses. Structurally, PTPN9 contains an N-terminal catalytic phosphatase domain and a C-terminal regulatory region with a lipid-binding SEC14 domain and a disordered proline-rich segment, enabling interactions with signaling molecules and membranes.
PTPN9 is notably implicated in cancer biology, where it acts as a tumor suppressor by negatively regulating oncogenic signaling pathways, including EGFR and HER2. Its dysregulation has been linked to malignancies, metabolic disorders, and autoimmune diseases. Recombinant PTPN9 protein is produced in vitro using expression systems like *E. coli* or mammalian cells (e.g., HEK293 or CHO), ensuring proper folding and post-translational modifications for functional studies. This recombinant form retains enzymatic activity, enabling researchers to investigate its substrate specificity, regulatory mechanisms, and interactions with signaling partners.
Studies utilizing PTPN9 recombinant protein have advanced understanding of its role in vesicular trafficking, insulin signaling, and immune cell activation. It also serves as a tool for drug discovery, particularly in identifying inhibitors or activators to modulate PTP activity for therapeutic purposes. Ongoing research continues to explore its potential as a biomarker or therapeutic target in diseases like breast cancer, diabetes, and rheumatoid arthritis.
×
